ASCO GU 2018: High-Dose Chemotherapy and Stem-Cell Rescue - Salvage Treatment for Germ Cell Testicular Tumors in Second- and Third-Line, and Outside Clinical Trials

San Francisco, CA ( Dr. Fernanda Ronchi and colleagues from Brazil provided results of their experience with high-dose chemotherapy and stem-cell rescue as salvage treatment among men with germ cell testicular tumors. Testicular tumors are the most common cancer in young males, usually curable in early stages. Therefore, only 25% of relapsed patients are long-term survivors. Previous non-randomized studies showed promising results with high-dose chemotherapy, however, the only randomized trial did not support this approach [1]. The objective of this study was to report the real-world use of high-dose chemotherapy and stem cell rescue in the second- and third-line at a Brazilian institution. 

ASCO GU 2018: Current Practice Patterns Surrounding Fertility Concerns in Stage I Seminoma Patients: Survey of United States Radiation Oncologists

San Francisco, CA ( Carl Post and colleagues presented results of their survey of US radiation oncologists with regards to their current practice patterns surrounding fertility concerns for stage I seminoma patients. Indeed, patients with testicular seminoma may face fertility issues because of their underlying disease as well as treatments they undergo. The current patterns of practice among US radiation oncologists aimed at assessing and preserving fertility in patients with stage I seminoma are unknown, thus forming the objective of the current study. The author’s hypothesis was that US radiation oncologists have embraced observation as the first-choice option for stage I seminoma patients.

ASCO GU 2018: Comparing Cabozantinib Treatment for a Cohort of Patients with Metastatic Clear Cell RCC and Variant Histology RCC: A Retrospective Study

San Francisco, CA ( Dr. Emily Lemke presented results of cabozantinib treatment of patients with metastatic RCC stratified by clear cell and variant histology. Both the randomized METEOR1 and CABOSUN trials2 in clear cell RCC found substantial benefit for patients receiving cabozantinib. To date, there has been no comparative data evaluating the utility of cabozantinib in clear cell RCC and variant histology RCC, thus forming the objective of the current study.

ASCO GU 2018: U-SMART: A Novel Scoring System of Preoperative Predictors to Stratify Oncologic Risk of Small Renal Mass

San Francisco, CA ( Dr. Kendrick Yim from UC San Diego presented their institution’s data assessing U-SMART, a novel scoring system of preoperative predictors to stratify oncologic risk of small renal mass. Small renal masses (< 4 cm in diameter) are heterogeneous, with significant proportions of benign as well as high-grade malignancy. The objective of this study was to develop a scoring system incorporating patient factors, serum markers, and morphometric characteristics to elucidate benign and high-grade pathology and guide decision making.

ASCO GU 2018: Can Health-Related Quality of Life Predict Conditional Survival in Metastatic RCC? Results from a Large Phase III Trial

San Francisco, CA ( Justin Doan presented on the effects of Health-Related Quality of Life (HRQoL) on conditional survival for patients with metastatic renal cell carcinoma (RCC). In the absence of mature overall survival (OS) endpoints, interim clinical trial data can be used to predict long-term survival in patients with advanced malignancies and inform trial continuation, treatment preference, and reimbursement decisions. HRQoL assessments may be associated with OS, offering potential utility for validated HRQoL scales. The objective of this study was to describe a predictive model used to determine the extent to which HRQoL data may predict conditional survival – ie. survival conditional on progression at either 6 or 12 months.

ASCO GU 2018: Characterization of the Benefit-Risk Profile of Nivolumab + Ipilimumab Sunitinib for Treatment-Naïve Advanced RCC (Checkmate 214)

San Francisco, CA ( Dr. Nizar Tannir presented on the characterization of the benefit-risk profile of nivolumab + ipilimumab vs sunitinib in the CheckMate 214 study. This study assessed nivolumab + ipilimumab vs sunitinib in the first line setting of metastatic RCC, noting a significant overall survival advantage for nivolumab + ipilimumab [1]. The objective of this study was to report additional data and define the benefit risk of nivolumab + ipilimumab, considering that in addition to a survival advantage, the immunotherapy regimen was well tolerated with acceptable safety considerations. 

ASCO GU 2018: Outcomes of Patients with Metastatic Clear-Cell RCC Treated with Second-Line VEGFR-TKI After First-Line Immune Checkpoint Inhibitors

San Francisco, CA ( Dr. Amishi Shah from the MD Anderson Cancer Center provided an analysis of outcomes of patients with metastatic clear cell RCC treated with second line VEGF-TKI after first line immune checkpoint inhibitors. There is a paucity of data that exists on objective response rates (ORR), progression-free survival (PFS), and safety of second-line VEGFR-TKI after first-line immune checkpoint inhibitor therapy in patients with metastatic clear-cell RCC. The objective of this study was to evaluate the above mentioned clinical endpoints. 

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.